LanZhou Foci Pharmaceutical Co.,Ltd.
Shenzhen Stock ExchangeTotal Valuation
LanZhou Foci Pharmaceutical Co.,Ltd. carries a market capitalization of 3.67B, placing it among publicly traded companies globally. Its enterprise value stands at 4.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.67B |
| Enterprise Value | 4.00B |
Share Statistics
LanZhou Foci Pharmaceutical Co.,Ltd. currently has 510.66M shares outstanding.
| Shares Outstanding | 510.66M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
LanZhou Foci Pharmaceutical Co.,Ltd. trades at a trailing price-to-earnings ratio of 101.48. The price-to-sales ratio is 6.31, and the price-to-book ratio stands at 3.26.
| PE Ratio | 101.48 |
| PS Ratio | 6.31 |
| PB Ratio | 3.26 |
| P/TBV Ratio | 2.53 |
| P/FCF Ratio | 406.44 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, LanZhou Foci Pharmaceutical Co.,Ltd. trades at an EV/EBITDA multiple of 36.58 and an EV/FCF ratio of 382.19. The EV/Sales ratio of 5.59 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 36.58 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.59 |
| EV / EBITDA | 36.58 |
| EV / EBIT | 36.58 |
| EV / FCF | 382.19 |
Financial Position
LanZhou Foci Pharmaceutical Co.,Ltd. maintains a current ratio of 3.04, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.53, indicating elevated leverage, while an interest coverage ratio of -120.15 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.04 |
| Quick Ratio | 1.26 |
| Debt / Equity | 1.53 |
| Debt / EBITDA | 0.26 |
| Interest Coverage | -120.15 |
Financial Efficiency
LanZhou Foci Pharmaceutical Co.,Ltd. posts a return on equity of 3.26 and a return on invested capital of 4.02.
| Return on Equity (ROE) | 3.26 |
| Return on Assets (ROA) | 1.79 |
| Return on Invested Capital (ROIC) | 4.02 |
| Return on Capital Employed (ROCE) | 3.24 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.51 |
Taxes
Over the trailing twelve months, LanZhou Foci Pharmaceutical Co.,Ltd. has paid 18.19M in income taxes, reflecting an effective tax rate of 29.97.
| Income Tax | 18.19M |
| Effective Tax Rate | 29.97 |
Stock Price Statistics
LanZhou Foci Pharmaceutical Co.,Ltd.'s stock has declined approximately -14.81043% over the past 52 weeks. The 50-day moving average sits at 7.70, while the 200-day moving average is 8.59.
| Beta (5Y) | N/A |
| 52-Week Price Change | -14.81043% |
| 50-Day Moving Average | 7.70 |
| 200-Day Moving Average | 8.59 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, LanZhou Foci Pharmaceutical Co.,Ltd. generated 716.29M in revenue and converted that into 44.51M in net income, yielding earnings per share of 0.08. EBITDA reached 109.44M, while operating income came in at 109.44M.
| Revenue | 716.29M |
| Gross Profit | 256.57M |
| Operating Income | 109.44M |
| Pretax Income | 60.69M |
| Net Income | 44.51M |
| EBITDA | 109.44M |
| EBIT | 109.44M |
| Earnings Per Share (EPS) | 0.08 |
Balance Sheet
LanZhou Foci Pharmaceutical Co.,Ltd. holds 565.24M in cash and equivalents against 28.68M in total debt, resulting in a net debt position of -541.24M. Total book value stands at 1.38B, with working capital of 915.32M providing operational flexibility.
| Cash & Cash Equivalents | 565.24M |
| Total Debt | 28.68M |
| Net Debt | -541.24M |
| Equity (Book Value) | 1.38B |
| Book Value Per Share | 2.71 |
| Working Capital | 915.32M |
Cash Flow
After subtracting -11.11M in capital expenditures, free cash flow totaled -11.11M - equivalent to -0.02 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -11.11M |
| Free Cash Flow | -11.11M |
| FCF Per Share | -0.02 |
Margins
LanZhou Foci Pharmaceutical Co.,Ltd. operates with a gross margin of 35.82, reflecting its pricing power and cost economics. The operating margin of 15.28 and net profit margin of 6.21 provide insight into operational efficiency.
| Gross Margin | 35.82 |
| Operating Margin | 15.28 |
| Pretax Margin | 8.47 |
| Profit Margin | 6.21 |
| EBITDA Margin | 15.28 |
Dividends & Yields
The company's payout ratio of 13.99 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.01 |
| Dividend Yield | N/A |
| Payout Ratio | 13.99 |
| Shareholder Yield | 0.26 |
| FCF Yield | 0.25 |
Stock Splits
LanZhou Foci Pharmaceutical Co.,Ltd.'s most recent stock split took place on August 14, 2015 with a 2:5 split ratio.
| Last Split Date | 8/14/2015 |
| Split Ratio | 2:5 |
Scores
LanZhou Foci Pharmaceutical Co.,Ltd. posts an Altman Z-Score of 5.27, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.27 |